Erythrodermic Psoriasis Treated with Secukinumab with Rapid and Sustained Resolution

Psoriasis is a chronic inflammatory skin disease. Generally, it has a negative impact in quality of life. New treatment options for moderate-to-severe psoriasis are available with the development of IL-17 inhibitors. Secukinumab is a fully human monoclonal immunoglobulin G1 κ antibody that selectively inhibits the ligand IL-17A. It seems to be more effective than other biologic medications and safe